Press Releases

Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Revolution Medicines Announces Commencement of Public Offering of Common Stock

Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio

Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024

Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress

Revolution Medicines to Participate in Upcoming Investor Conferences

Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024

Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma